Summary 2,3,5-Trimethyl-6-(3-pyridylmethyl)1,4-benzoquinone (CV-6504), an inhibitor of 5-lipoxygenase and thromboxane A2 synthase and a scavenger of active oxygen species, has been shown to exhibit profound antitumour activity against three established murine adenocarcinomas (MACs) that are generally refractory to standard cytotoxic agents. For the cachexia-inducing MAC16 tumour, optimal anti-tumour activity was seen at dose levels of 10 and 25 mg kg -day -, together with a reversal of cachexia and a doubling of the time to sacrifice of the animals through cachexia from 8 days to 17 days. The remaining tumour fragments showed extensive necrosis in regions distal from the blood supply. Growth of the MAC13 tumour was also effectively suppressed at dose levels between 5 and 50 mg kg-l day-1, resulting in a specific growth delay between 1.0 and 1.2. Growth of the MAC26 tumour was also inhibited in a concentration-related manner, with doses of 25-50 mg kg-' day-1 being optimal. Anti-tumour activity towards all three tumours at low dose levels of CV-6504 was effectively suppressed by concurrent administration of linoleic acid (1 g kg-' day-'), suggesting that inhibition of linoleate metabolism was responsible for the anti-tumour effect. Tumour sensitivity may be correlated with increased DT-diaphorase levels that are required to metabolise CV-6504 to the active hydroquinone, which inhibits 5-lipoxygenase activity.
There is a growing body of evidence suggesting a role for polyunsaturated fatty acids (PUFAs), and in particular linoleic acid (LA) and arachidonic (AA) acid, as tumour promoters (Welsch, 1987) and as regulators of the growth of solid tumours (Hussey and Tisdale, 1994) and their metastasis (Chen et al., 1992) . The anti-proliferative but not the anticachectic effect of eicosapentaenoic acid (EPA) against the MAC16 tumour was reversed by concurrent administration of LA (Hudson et al., 1993) , suggesting that LA released from adipose tissue during the process of cachexia may be important for tumour growth. Significantly lower levels of LA as a percentage of total fatty acids were observed in plasma phospholipids, and cholesterol esters and in red blood cell phospholipids in patients with cachexia (Mosconi et al., 1989) suggesting that human tumours may also be dependent on this essential fatty acid.
Studies in vitro (Hussey and Tisdale, 1994; Rose and Connolly, 1990) have suggested that metabolism of PUFA through the lipoxygenase pathway may be important for stimulation of tumour growth. Lipoxygenases constitute a family of closely related non-haeme iron-containing dioxygenases that convert PUFA to the corresponding hydroperoxy derivatives. In mammalian cells at least four types of lipoxygenase can be discriminated on the basis of the carbon atom of the substrate molecule (AA) at which oxygen is introduced: the 5-lipoxygenase, two 12-lipoxygenases (platelet type and leucocyte type) and the 15-lipoxygenases. Metabolism through the 12-lipoxygenase pathway may be most important for tumour growth and metastasis. Thus 12-(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) has been suggested (Liu et al., 1994) as a determinant of the metastatic potential of tumour cells and may be a crucial target for intervention in metastasis. 12(S)-HETE has been shown to stimulate DNA synthesis in fetal bovine aortic endothelial cells (Setty et al., 1987) and to regulate expression of the proto-oncogenes c-fos and c-myc in rat lens epithelial cells (Lysz et al., 1994) , whereas 12(R)-HETE formed from AA by a cytochrome P450-dependent pathway caused neovascularisation of the cornea (Masferrer et al., 1991) . This could explain why inhibitors of the AA cascade exert anti-angiogenic activity in an in vivo model system of tumour angiogenesis in mice and inhibit tube formation in vitro (Ito et al., 1993) . Growth factors such as epidermal growth factor (EGF) enhance 12-HETE formation from AA (Chang et al., 1992) and the hydroxy and hydroperoxy metabolites of LA enhance EGF-stimulated [3H]thymidine incorporation in Balb/c 3T3 cells (Glasgow and Eling, 1990) , suggesting that these metabolites may be part of the signal transduction cascade initiated by EGF.
These results suggest that inhibitors of the lipoxygenase pathways may provide useful new agents to inhibit tumour growth and metastasis. A number of inhibitors have been synthesised, mainly of the 5-lipoxygenase pathway. The present report concerns the novel anti -tumour activity of 2,3,5 -trimethyl -6 -(3 -pyridylmethyl) -1,4 -benzoquinone (CV-6504) against established colon adenocarcinomas of the MAC series which are refractory to standard cytotoxic agents (Double and Bibby, 1989) and which require PUFA for growth stimulation (Hussey and Tisdale, 1994) . CV -6504 has inhibitory activity against both 5 -lipoxygenase and thromboxane A2 synthase as well as scavenging activity against active oxygen species (Ohkawa et al., 1991a,b) . The agent has undergone clinical investigation for the treatment of chronic glomerular nephritis.
Materials and methods Animals
Pure-strain male NMRI mice were obtained from our own inbred colony under conventional conditions and were fed a rat and mouse breeding diet of which 50% of the energy was supplied by carbohydrate and 11.5% as fat. Linoleic acid comprised 4.5% of the fat giving a daily consumption of 45 mg (Hussey and Tisdale, 1994 adenocarcinomas of the colon (MACs) were originally produced by prolonged administration of 1,2-dimethylhydrazine (Double et al., 1975 for MAC26 7 + 1 and for MAC 13 3 + 1 ,UM. These values were about 10-fold lower than previously observed with the cyclooxygenase inhibitor indomethacin (Hussey and Tisdale, 1994) . The IC50 value to MAC16 was not increased by extracellular glutathione levels between 1 and 100 ptM, suggesting that it did not react with glutathione in vitro. The MAC tumours are relatively slow growing in vivo with volume doubling times of 4 days (MAC16), 3.5 days (MAC13) and 3 days (MAC26) and show varying degrees of differentiation. The effect of CV-6504 on the growth of the MAC1 6 tumour and the effect on host body weight loss is shown in Figure 1 . Therapy was initiated 9 days after transplantation when the tumour volume was 100 mm3. The (Figure 3a ). There was extensive necrosis and a fibrous capsule which walled in the few remaining viable cells and areas of necrosis (Figure 3b ). Control MAC16 tumours showed little necrosis and no capsule (Figure 3c ). Growth of the MAC13 tumour was also effectively suppressed by administration of CV-6504 at dose levels between 5 and 50 mg kg-' day-' (Figure 4a ). Lower dose levels (5 and 10 mg kg-' day-') appeared to produce more effective tumour suppression and a higher specific growth delay than higher doses (Table I ). Growth inhibition produced by CV-6504 at 5 mg kg-1 day-1 was reduced by co-administration of LA (1 g kg-1 day-1) ( Figure 4b ) but this effect was counteracted by increasing the dose of CV-6504 to 10 mg kg-1 day-1 (Figure 4c ). Histological examination of sections of treated tumour compared with control revealed significant morphological effects. Control sections (Figure 5a ) demonstrated the typical glandular pattern of this tumour, whereas treatment resulted in central necrosis (Figure 5b, c) with evidence of lymphocyte infiltration. The effect of lower dose levels of CV-6504 on growth of the MAC13 tumour was addressed in a second experiment (Figure 6 ). This showed that a dose level of 5 mg kg-1 day-' produced a significantly greater growth inhibition of the MAC13 tumour than did the lower dose levels.
Growth of the MAC26 tumour was also inhibited by CV-6504 in a dose-related manner (Figure 7 ). This tumour was less sensitive to CV-6504 than the other MAC tumours and dose levels of 25 and 50 mg kg-' day-' were found to be optimal (Table I) . Again a reduction of the anti-tumour effect of CV-6504 (25 mg kg-' day-') was observed with concurrent administration of LA (1 g kg-1 day-').
Discussion
Previous studies (Double and Bibby, 1989) have demonstrated the MAC tumour series to be generally refractory to standard cytotoxic agents, with the MAC13 probably being the most responsive. In contrast with this general lack of responsiveness the present study demonstrates profound antitumour activity of CV-6504 against three established MAC tumours in an in vivo assay. For most anti-tumour agents activity is usually only demonstrated at the maximum tolerated dose. Thus the therapeutic index for the standard nitrosoureas against chemoresponsive tumours such as the MAC13 is < 1 and even against the L1210 leukaemia is no higher than 7 (Double and Bibby, 1989) . This study demonstrates optimal anti-tumour activity of CV-6504 against the MAC16 tumour at 10 mg kg-' day-', against the MAC13 tumours at 5 -10 mg kg ' day ' and against the MAC26 tumour at 50 mg kg-day-'. Chronic toxicity studies showed that the non-toxic dosage level in male mice was 100 mg kg-' day-'. Thus CV-6504 not only demonstrated profound anti-tumour activity against previously chemoresistant animal models, but did so at a dose with a high margin of safety. This dose is comparable with that previously employed for the inhibition of puromycin aminonucleoside nephrosis in rats (Shibouta et al., 1991) .
The MAC16 tumour was found to be more responsive to CV-6504 than the MAC26 tumour (Table I) . Mitomycin C and doxorubicin are the only two other chemotherapeutic agents which are more effective against MAC16 than MAC26 (Double and Bibby, 1989) . These are also quinone-containing drugs that can undergo metabolic reduction and for mitomycin C there is evidence to suggest activation by DT-diaphorase (Siegal et al., 1990) . Previous studies on the mode of action of CV-6504 suggest a reduction to the hydroquinone by two electron-donating enzymes such as DT-diaphorase without the intermediary of a semiquinone radical (Ohkawa et al., 1991b) . Lipid peroxidation as well as 5-lipoxygenase activity is prevented by reducing the ferric iron in the active site of the enzyme to the ferrous (resting state) and unlike a number of antitumour quinones, CV-6504 is capable of scavenging active oxygen species. The increased sensitivity of the MAC 16 to CV-6504 could be correlated with an increased DTdiaphorase activity that has been reported to be 16-fold higher than in the MAC26 tumour (Collard, 1994) with the MAC13 tumour displaying a similar low value. Certainly CV-6504 is an excellent substrate for both human and mouse DT-diaphorase with a kcat of 6 x 104 min-' and Km of 50 gIM (RJ Knox, Personal communication) . These results can be compared with the classic DT-diaphorase substrate menadione, which has the same kcat, but a Km of only 0) Cytotoxicity of quinones decreases with increasing methyl substitution of the nucleus with the higher redox potential benzoquinones being the most cytotoxic (O'Brien, 1991) . The fully substituted benzoquinone 2,3,5,6 tetramethylbenzoquinone (duroquinone) does not form glutathione conjugates or alkylate proteins and is only weakly cytotoxic. It may be expected by comparison that would also show low reactivity, which would explain the lack of effect of glutathione on cytotoxicity in vitro and the low toxicity to the whole animal. Anti-tumour activity of CV-6504 towards the MAC16, MAC13 and MAC26 tumours at low dose levels was reduced by the concomitant administration of pure LA
(1 g kg-' day-'). This suggests that the anti-tumour effect of CV-6504 is mediated through inhibition of the metabolism of LA. Higher dose levels of the drug were able to overcome the effect of LA suggesting a competitive effect. Further studies are required to completely evaluate the mode of action of this novel agent and in particular which pathway of LA metabolism is related to the anti-tumour activity. However, the wide spectrum of anti-tumour activity, against what are generally considered to be chemoresistant tumours, combined with a high measure of safety, identifies CV-6504 as a potential agent for clinical investigation.
